

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Smith Christopher Charles</u> <hr/> (Last) (First) (Middle) <u>2995 WATERTOWN ROAD</u> <hr/> (Street) <u>LONG LAKE MN 55356</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>12/02/2025</u>	3. Issuer Name and Ticker or Trading Symbol <u>Park Dental Partners, Inc. [ PARK ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock<sup>(1)</sup></u>	<u>2,800</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

**Explanation of Responses:**

1. Includes 2,800 shares of restricted stock issued to the Reporting Person (the "Restricted Stock"), which shares vest as follows: (i) 25% on the completion of the Issuer's initial public offering; and (ii) thereafter, at the rate of 6.25% per quarter. The Restricted Stock is subject to accelerated vesting in connection with a change in control of the Issuer in accordance with the terms of the Park Dental Partners, Inc. 2023 Restricted Stock Plan and the applicable award agreement. The Restricted Stock does not confer any voting rights until the applicable shares have vested and the holder of Restricted Stock has become the record owner of such vested shares.

/s/ Maxwell Black as  
Attorney-in-Fact for Philip Smith  
12/03/2025

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY The undersigned, in his or her capacity as a director or officer of Park Dental Partners, Inc. (the "Company"), constitutes and appoints Maxwell Black of Winthrop & Weinstine, P.A. as his or her true and lawful attorney-in-fact, with full power of substitution, to: (a) execute for and on behalf of the undersigned, in the undersigned's capacity as a director or officer of the Company, Forms 3, 4 and 5 (and any amendments thereto) required to be filed by the undersigned under Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations thereunder; (b) prepare, execute and file, for and on behalf of the undersigned, Schedules 13D and 13G (and any amendments thereto), together with any related exhibits, cover pages, certifications and documents, including any joint filing agreements, required to be filed by the undersigned under Section 13 of the Exchange Act, and the rules and regulations thereunder; (c) prepare, execute and file for and on behalf of the undersigned electronic Forms 144 (and any amendments thereto), together with any related certifications or documents reasonably necessary to effect such filings; (d) prepare, execute and submit, on the undersigned's behalf, Form ID applications, updates, and renewals, and take any actions reasonably necessary to obtain, maintain, recover or' update Electronic Data Gathering, Analysis, and Retrieval ("EDGAR") access credentials for the undersigned, including Central Index Key ("CIK") assignment, access codes, passphrases, multi-factor authentication and role designations under EDGAR Next; (e) cause the Company to accept a delegation of authority from any of the undersigned's EDGAR account administrators and, pursuant to that delegation, authorize the Company's EDGAR account administrators to appoint, remove or replace users for the undersigned's EDGAR account; (f) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete, file and submit the foregoing documents with the U.S. Securities and Exchange Commission through the EDGAR system, including coordinating with the Company, its transfer agent, equity plan administrator, and brokers (each as applicable) to obtain holdings and transaction information, and preparing, submitting and correcting any amendments; and (g) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion consistent with the scope of authority granted herein. The undersigned hereby grants to the attorney-in-fact full power and authority to do and perform any act necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do personally, with full power of substitution or revocation, hereby ratifying and confirming all that the attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. This Power of Attorney is limited to the purposes described above and does not authorize the attorney-in-fact to take any action on behalf of the undersigned other than with respect to the preparation, execution and filing of Schedules 13D and 13G, Forms 3, 4 and 5, electronic Forms 144, and Form ID and associated EDGAR Next account administration, and actions reasonably incidental thereto (including the use and retention of electronic signatures and approvals in compliance with Regulation S-T). Nothing herein authorizes the attorney-in-fact to make investment decisions, execute trades, or direct the undersigned's brokerage accounts. This Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to the attorney-in-fact. This Power of Attorney may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument. Signatures delivered by electronic transmission (including any electronic signature compliant with Regulation S-T) shall be deemed original for all purposes. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 22nd day of October, 2025. Signed by: /s/ Philip Smith